Clinical Study "Common" Name (formal title)	Number of enrollees	Funding source (pharmaceutical company/National Institutes of Health [NIH])	Year complete	Primary publication	Full study treatment protocol/patient disposition
POINT   Periocular Triamcinolone Versus Intravitreal Triamcinolone Versus Intravitreal Dexamethasone Implant for the Treatment of Uveitic Macular Edema: The PeriOcular versus INTravitreal Corticosteroids for Uveitic Macular Edema (POINT) Trial	192	National Eye Institute (NEI)/National Institutes of Health (NIH) (NCT02374060)	2018	The Multicenter Uveitis Steroid Treatment Trial (MUST) Research Group, Thorne JE, Sugar EA, et al. Periocular triamcinolone versus intravitreal triamcinolone versus intravitreal dexamethasone implant for the treatment of uveitic macular edema: The PeriOcular versus INTravitreal corticosteroids for uveitic macular edema (POINT) Trial. Ophthalmology. 2019;126:283-295. https://www.aaojournal.org/article/S0161-6420(18)31133-3/fulltext